Kosiński Sylweriusz, Darocha Tomasz, Jarosz Anna, Zeliaś Aleksander, Ziętkiewicz Mirosław, Podsiadło Paweł, Sanak Tomasz, Sałapa Kinga, Piątek Jacek, Konstany-Kalandyk Janusz, Gałązkowski Robert, Krawczyk Paweł, Krzych Łukasz, Drwiła Rafał
Department of Anesthesiology and Intensive Care, Pulmonary Hospital, Zakopane, Poland.
Tatra Mountain Rescue Service, Zakopane, Poland.
Scand J Trauma Resusc Emerg Med. 2017 May 2;25(1):46. doi: 10.1186/s13049-017-0388-7.
Recently, veno-arterial extracorporeal membrane oxygenation (VA-ECMO) has become the rewarming treatment of choice in hypothermic cardiac arrest. The detailed indications for extracorporeal rewarming in non-arrested, severely hypothermic patients with circulatory instability have not been established yet. The primary purpose of the study was a preliminary analysis of all aspects of the treatment process, as well as initial identification of mortality risk factors within the group of severely hypothermic patients, treated with arteriovenous extracorporeal membrane oxygenation (VA-ECMO). The secondary aim of the study was to evaluate efficacy of VA-ECMO in initial 6-h period of treatment METHODS: From July 2013 to June 2016, thirty one hypothermic patients were accepted for extracorporeal rewarming at Severe Accidental Hypothermia Center, Cracow. Thirteen patients were identified with circulatory instability and were enrolled in the study. The evaluation took into account patients' condition on admission, the course of therapy, and changes in laboratory and hemodynamic parameters.
Nine out of 13 analyzed patients survived (69%). Patients who died were older, had lower both systolic and diastolic pressure, and had increased creatinine an potassium levels on admission. In surviving patients, arterial blood gases parameters (pH, BE, HCO) and lactates would normalize more quickly. Their potassium level was lower on admission as well. The values of the core temperature on admission were comparable. Although normothermia was achieved in 92% of patients, none of them had been weaned-off VA-ECMO in the first 6 h of treatment.
In our preliminary study more pronounced markers of cardiocirculatory instability and organ hypoperfusion were observed in non-survivors. Future studies on indications to extracorporeal rewarming in severely hypothermic, non-arrested patients should focus on the extent of hemodynamic disturbances. Short term (<6 h) treatment in severe hypothermic, non-arrested patients seems to be not clinically appropriate.
最近,静脉-动脉体外膜肺氧合(VA-ECMO)已成为低温心脏骤停复温治疗的首选方法。对于未发生心脏骤停、严重低温且循环不稳定的患者,体外复温的详细指征尚未确定。本研究的主要目的是对治疗过程的各个方面进行初步分析,并初步确定接受动静脉体外膜肺氧合(VA-ECMO)治疗的严重低温患者群体中的死亡风险因素。本研究的次要目的是评估VA-ECMO在治疗最初6小时内的疗效。
2013年7月至2016年6月,31例低温患者在克拉科夫严重意外低温中心接受体外复温治疗。其中13例患者被确定存在循环不稳定并纳入研究。评估考虑了患者入院时的状况、治疗过程以及实验室和血流动力学参数的变化。
13例分析患者中有9例存活(69%)。死亡患者年龄较大,入院时收缩压和舒张压较低,肌酐和钾水平升高。存活患者的动脉血气参数(pH值、碱剩余、碳酸氢根)和乳酸水平恢复正常的速度更快。他们入院时的钾水平也较低。入院时的核心温度值相当。尽管92%的患者实现了体温正常,但在治疗的前6小时内,没有患者成功撤离VA-ECMO。
在我们的初步研究中,未存活者出现了更明显的心脏循环不稳定和器官灌注不足的指标。未来关于严重低温、未发生心脏骤停患者体外复温指征的研究应关注血流动力学紊乱的程度。对严重低温、未发生心脏骤停患者进行短期(<6小时)治疗似乎在临床上并不合适。